- Home
- CANF vs GLBZ Comparison
CANF vs GLBZ Comparison
Compare CANF & GLBZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- GLBZ
- Stock Information
- Founded
- CANF 1994
- GLBZ 1949
- Country
- CANF Israel
- GLBZ United States
- Employees
- CANF N/A
- GLBZ N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- GLBZ Major Banks
- Sector
- CANF Health Care
- GLBZ Finance
- Exchange
- CANF Nasdaq
- GLBZ Nasdaq
- Market Cap
- CANF 13.5M
- GLBZ 14.1M
- IPO Year
- CANF N/A
- GLBZ N/A
- Fundamental
- Price
- CANF $1.04
- GLBZ $5.50
- Analyst Decision
- CANF Strong Buy
- GLBZ
- Analyst Count
- CANF 2
- GLBZ 0
- Target Price
- CANF $14.00
- GLBZ N/A
- AVG Volume (30 Days)
- CANF 144.3K
- GLBZ 18.3K
- Earning Date
- CANF 08-29-2025
- GLBZ 07-25-2025
- Dividend Yield
- CANF N/A
- GLBZ 1.72%
- EPS Growth
- CANF N/A
- GLBZ N/A
- EPS
- CANF N/A
- GLBZ 0.01
- Revenue
- CANF $674,000.00
- GLBZ $11,536,000.00
- Revenue This Year
- CANF $461.72
- GLBZ N/A
- Revenue Next Year
- CANF N/A
- GLBZ N/A
- P/E Ratio
- CANF N/A
- GLBZ $442.74
- Revenue Growth
- CANF N/A
- GLBZ N/A
- 52 Week Low
- CANF $0.98
- GLBZ $4.02
- 52 Week High
- CANF $4.69
- GLBZ $6.99
- Technical
- Relative Strength Index (RSI)
- CANF 43.65
- GLBZ 57.20
- Support Level
- CANF $1.00
- GLBZ $5.58
- Resistance Level
- CANF $1.05
- GLBZ $5.84
- Average True Range (ATR)
- CANF 0.03
- GLBZ 0.42
- MACD
- CANF 0.00
- GLBZ 0.06
- Stochastic Oscillator
- CANF 45.00
- GLBZ 79.57
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.